Opthea | OPT

Stock Price
0.58
Daily Change
0%
Yearly
-47.73%
Q2 Forecast
0.59
Rating
Sell

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Cochlear 239.48 -1.24 -0.52% 11.62%
CSL 305.30 -0.45 -0.15% 12.50%
Fisher & Paykel Healthcare 21.50 -0.32 -1.47% 18.13%
Nanosonics 4.62 -0.06 -1.28% 42.59%
Paradigm Biopharmaceuticals 0.91 -0.02 -2.16% -20.61%
Pacific Edge 0.10 -0.002 -1.96% -86.11%
Pacific Smiles 1.35 -0.01 -0.74% -16.41%
PYC Therapeutics 0.06 0 0% -21.43%
Ramsay Health Care 57.70 -0.47 -0.81% -25.52%
ResMed 32.15 -0.10 -0.31% 8.29%
Telix Pharmaceuticals 10.28 -0.18 -1.72% 155.09%


Opthea

Opthea Ltd traded at 0.58 this Friday June 9th, decreasing 0 or 0 percent since the previous trading session. Looking back, over the last four weeks, Opthea lost 16.67 percent. Over the last 12 months, its price fell by 47.73 percent. Looking ahead, we forecast Opthea Ltd to be priced at 0.59 by the end of this quarter and at 0.55 in one year, according to Trading Economics global macro models projections and analysts expectations.

Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing novel therapies to treat highly prevalent and progressive retinal eye diseases including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Company’s lead product candidate OPT-302 is in pivotal Phase III clinical trials and being developed for use in combination with anti- Vascular Endothelial Growth Factor (VEGF-A) monotherapies to achieve broader inhibition of the VEGF family. OPT-302 has the potential to address the unmet medical need of wet age-related macular degeneration (AMD) and diabetic macular edema (DME) patients, many of whom respond sub-optimally or become refractory to existing therapies for these debilitating diseases. The Company is advancing the clinical development of OPT-302 in wet AMD and DME clinical trials.